Page last updated: 2024-10-15

azaguanine

Description

Azaguanine: One of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

8-azaguanine : A triazolopyrimidine that consists of 3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidine bearing amino and oxo substituents at positions 5 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135403646
CHEMBL ID374107
CHEBI ID63486
SCHEMBL ID26816
SCHEMBL ID16056969
MeSH IDM0002061

Synonyms (130)

Synonym
5-amino-3,6-dihydro-(1,2,3)triazolo(4,5-d)pyrimidin-7-one
MLS001074752 ,
smr000112575
5-amino-3h-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol
OPREA1_862850
NCI60_041639
NCIMECH_000065
7h-1,3-triazolo[4,5-d]pyrimidin-7-one, 5-amino-1,4-dihydro-
v-triazolo[4, 5-amino-
wln: t56 bnnm fvm inj hz
nsc-749
7h-v-triazolo[4, 5-amino-1,6-dihydro-
PRESTWICK3_000001
7h-1,2,3-triazolo[4,5-d]pyrimidin-7-one, 5-amino-1,4-dihydro-
PRESTWICK_40
azaguanine-8
ml068
NCGC00016399-01
PRESTWICK2_000001
BPBIO1_000003
{7h-v-triazolo[4,5-d]pyrimidin-7-one,} 5-amino-1, 6-dihydro-
8-azaguanine
NSC749 ,
triazologuanine
nsc223526
azan
sk 1150
guanazolo
azaguanine
azaguanine,8
8 ag
5-amino-3,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
guanazol
134-58-7
pathocidin
{7h-1,2,3-triazolo[4,5-d]pyrimidin-7-one,} 5-amino-1,4-dihydro-
pathocidine
BSPBIO_000001
OPREA1_163604
azg ,
5-amino-1h-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol
AP-770/40205766
5-amino-3,6-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
8-azaguanine, hybri-max(tm), gamma-irradiated, powder, bioxtra, suitable for hybridoma
3-amino-2,4,7,8,9-pentazabicyclo[4.3.0]nona-1,3,6-trien-5-one
DB01667
nsc-223526
OPREA1_695327
ccris 2758
7h-1,2,3-triazolo(4,5-d)pyrimidin-7-one, 5-amino-1,4-dihydro-
7h-v-triazolo(4,5-d)pyrimidin-7-one, 5-amino-1,6-dihydro-
nsc 223526
5-amino-7-hydroxy-1h-v-triazolo(d)pyrimidine
nsc 749
5-amino-1h-v-triazolo(d)pyrimidin-7-ol
c4h4n6o
7h-1,2,3-triazolo(4,5-d)pyrimidinone, 5-amino-1,4-dihydro-
v-triazolo(4,5-d)pyrimidin-7-ol, 5-amino-
ai3-25015
sf-337
b-28
einecs 205-148-1
5-amino-1h-triazolo(4,5-d)pyrimidin-7-ol
5-amino-1,4-dihydro-7h-1,2,3-triazolo(4,5-d)pyrimidin-7-one
5-amino-1,6-dihydro-7h-v-triazolo(4,5-d)pyrimidin-7-one
PRESTWICK1_000001
SPBIO_001922
PRESTWICK0_000001
A0625
chebi:63486 ,
CHEMBL374107
5-amino-2,3-dihydrotriazolo[4,5-d]pyrimidin-7-one
AKOS003382261
HMS1568A03
AKOS002271137
2-(2,4-dimethylphenoxy)acetic acid;azaguanine-8
A806807
NCGC00188264-01
HMS2095A03
AKOS006223655
HMS2269M18
S4194
CCG-35353
5-imino-4,6-dihydro-3h-1,2,3-triazolo[5,4-d]pyrimidin-7-one
unii-q150359i72
q150359i72 ,
FT-0621501
5-amino-1h-triazolo[4,5-d]pyrimidin-7-ol
bdbm96998
cid_8646
5-azanyl-2,3-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
EPITOPE ID:167837
S11846
AKOS015854480
2-amino-6-hydroxy-8-azapurine
8-azaguanine [mi]
5-amino-2,3-dihydrotriazolo(4,5-d)pyrimidin-7-one
8azag
CCG-220001
SCHEMBL26816
SCHEMBL16056969
5-amino-1h-[1,2,3]triazolo[4,5-d]pyrimidin-7(6h)-one
5-amino-3,6-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one #
azaguanine, 8
Q-200564
DTXSID0074508
mfcd00056937
AKOS026750385
SR-01000763820-2
sr-01000763820
7h-1,2,3-triazolo[4,5-d]pyrimidin-7-one, 5-amino-3,6-dihydro-
HMS3652J09
8-azaguanin
HMS3712A03
1850358-61-0
SW196356-3
5-amino-3h-[1,2,3]triazolo[4,5-d]pyrimidin-7(6h)-one
CS-0013169
HY-B1468
Q4644262
SY052313
5-amino-1,4-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
DS-16103
5-amino-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
5-amino-1h-[1,2,3]triazolo-[4,5-d]pyrimidin-7(6h)-one
bdbm50465709
NCGC00016399-03
CS-0513856
5-amino-2h-[1,2,3]triazolo[4,5-d]pyrimidin-7(3h)-one
5-amino-1,6-dihydrotriazolo[4,5-d]pyrimidin-7-one

Research Excerpts

Overview

8-azaguanine is a triazolopyrimidine nucleobase analog. It has been implicated as a lead molecule in cancer and malaria therapy.

ExcerptReference
"8-azaguanine is a triazolopyrimidine nucleobase analog possessing potent antibacterial and antitumor activities, and it has been implicated as a lead molecule in cancer and malaria therapy. "( Tautomeric equilibrium and spectroscopic properties of 8-azaguanine revealed by quantum chemistry methods.
Maciejczyk, M; Pyrka, M, 2023
)

Toxicity

ExcerptReference
" Virtually non toxic concentrations of dThd potentiated the cytotoxicity of MNNG more than 10-fold but that of MMS was potentiated only about 2-fold showing that O-alkylation of DNA was associated not only with the facilitation of mutagenesis but also with the potentiation of cytotoxicity."( Deoxyribonucleoside-induced selective modulation of cytotoxicity and mutagenesis.
Danenberg, PV; Ibric, LL; Peterson, AR; Peterson, H, 1985
)
"8-azaguanine and 6-thioguanine were both toxic to non-dividing liver cells in primary cultures."( Toxicity of 6-thioguanine and 8-azaguanine to non-dividing liver cell cultures.
Berman, JJ; Tong, C; Williams, GM, 1985
)

Dosage Studied

ExcerptReference
" Previous reports that caffeine enhances induced mutation frequencies are explained by an artefact in the situ method used; a similar artefact may also explain the cumulative in situ mutation dose-response curves."( Failure of caffeine to influence induced mutation frequencies and the independence of cell killing and mutation induction in V79 Chinese hamster cells.
Fox, M; McMillan, S, 1979
)
" These results can account for many of the anomalies encountered in previous studies with purine analogues as selective agents, and show that some care has to be taken to characterize the mutants selected by resistance to purine analogues before meaningful dose-response relationships can be established."( Factors affecting the efficiency of purine analogues as selective agents for mutants of mammalian cells induced by ionising radiation.
Stephens, MA; Stretch, A; Thacker, J, 1976
)
" The dose-response relationship for mutant induction by protons, as determined at the optimal expression time, was compared to that obtained after gamma rays."( Induction of 8-azaguanine resistant mutants in human cultured cells exposed to 31 MeV protons.
Francone, G; Fuhrman Conti, AM; Gallini, RE; Volonte, M, 1988
)
" The dose-response relationship does not appear to deviate from linearity."( Determination of the expression time and the dose--response relationship for mutations at the HGPRT (hypoxanthine-guanine-phosphophoribosyl transferase) locus induced by X-irradiation in human diploid skin fibroblasts.
de Ruijter, YC; Simons, JW, 1980
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitorAn EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of purine nucleoside phosphorylase (EC 2.4.2.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triazolopyrimidines
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.94330.140911.194039.8107AID2451
BRCA1Homo sapiens (human)Potency11.22020.89137.722525.1189AID624202
15-lipoxygenase, partialHomo sapiens (human)Potency0.00320.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency5.73010.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency12.38070.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency7.94330.00137.762544.6684AID914; AID915
67.9K proteinVaccinia virusPotency20.19030.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency0.51740.005210.865235.4813AID686970
hemoglobin subunit betaHomo sapiens (human)Potency1.65310.31629.086131.6228AID1405; AID925
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency10.00000.316212.443531.6228AID924
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency79.43280.010039.53711,122.0200AID1479
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency7.43600.004611.374133.4983AID624296; AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.08910.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency6.44710.058010.694926.6086AID602310; AID651812; AID651813
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency5.79970.025911.239831.6228AID651814; AID651815
Glycoprotein hormones alpha chainHomo sapiens (human)Potency2.81844.46688.344810.0000AID624291
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcriptional activator protein LasRPseudomonas aeruginosa PAO1IC50 (µMol)0.64000.11003.15839.0000AID1414074
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_aHomo sapiens (human)EC50 (µMol)91.17003.38103.38103.3810AID686991
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microphthalmia-associated transcription factorHomo sapiens (human)AC500.87500.015010.904946.0480AID493073; AID493102; AID493177
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Km72.00001.15002.75635.9000AID274549
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (108)

Processvia Protein(s)Taxonomy
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID274547Inhibition of [3H]hypoxanthine uptake in Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID274563Inhibition of Plasmodium falciparum HGXPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1414074Antagonist activity at LasR in Pseudomonas aeruginosa PAO1 harboring GFP-fused quorum sensing lasB measured every 15 mins for 14 hrs by GFP reporter gene assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Pseudomonas aeruginosa Quorum Sensing Systems as Drug Discovery Targets: Current Position and Future Perspectives.
AID274549Inhibition of human HGPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID274562Inhibition of human HGPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1136398Inhibition of human erythrocyte purine nucleoside phosphorylase assessed as inhibition of guanosine phosphorylysis at 4 umol after 30 mins by orcinol reaction1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID79405Cytotoxicity against H.Ep cells in the presence of 0.1 ug/mL pentostatin;ND means no data.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Synthesis and biological evaluation of 2-fluoro-8-azaadenosine and related compounds.
AID79401Cytotoxicity against H.Ep cells1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Synthesis and biological evaluation of 2-fluoro-8-azaadenosine and related compounds.
AID153712Percent increase in life span of P388 leukemia cells (10e6) infected(ip) mice at dose of 50 (400) mg/kg, ip: qd 1-5 schedule; ND means no data1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Synthesis and biological evaluation of 2-fluoro-8-azaadenosine and related compounds.
AID274548Antiplasmodial activity against Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (797)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990727 (91.22)18.7374
1990's27 (3.39)18.2507
2000's17 (2.13)29.6817
2010's21 (2.63)24.3611
2020's5 (0.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.24%)5.53%
Reviews24 (2.90%)6.00%
Case Studies2 (0.24%)4.05%
Observational0 (0.00%)0.25%
Other800 (96.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]